Fasting triglyceride concentration: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

R-lipoic acid did not reduce the primary fasting-triglyceride outcome in this 24-week trial.
Free R-alpha-lipoic acid → Fasting triglyceride concentration source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/ala-research/32692358.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4054eff822014466ea739125fd4000ba2a5852e5f9818487f0b32b7be2b8d076", "start_char": 0, "end_char": 2088, "text_sha256": "4054eff822014466ea739125fd4000ba2a5852e5f9818487f0b32b7be2b8d076"}
experimental_model
Randomized placebo-controlled R-lipoic-acid trial
exposure
R-lipoic acid 600 mg/day for 24 weeks
limitations
Primary triglyceride outcome was null; BMI was secondary and subgroup findings are exploratory.
nutrient_topic
Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
organism
Human
plain_language
The trial’s main blood-fat target did not improve.
primary_references
[ala-p32692358] A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations. (2020). https://pubmed.ncbi.nlm.nih.gov/32692358/ DOI: 10.1093/jn/nxaa203
tissue_or_cell_type
81 overweight adults with elevated triglycerides
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1209–1220
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled R-lipoic-acid trial · source_derived_draft · unverified_draft
### ala-triglyceride-primary-null R-lipoic acid did not reduce the primary fasting-triglyceride outcome in this 24-week trial. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial’s main blood-fat target did not improve. organism: Human tissue_or_cell_type: 81 overweight adults with elevated triglycerides experimental_model: Randomized placebo-controlled R-lipoic-acid trial limitations: Primary triglyceride outcome was null; BMI was secondary and subgroup findings are exploratory. exposure: R-lipoic acid 600 mg/day for 24 weeks evidence_span: {"source_cache": "artifacts/ala-research/32692358.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4054eff822014466ea739125fd4000ba2a5852e5f9818487f0b32b7be2b8d076", "start_char": 0, "end_char": 2088, "text_sha256": "4054eff822014466ea739125fd4000ba2a5852e5f9818487f0b32b7be2b8d076"} [ala-p32692358] A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations. (2020). https://pubmed.ncbi.nlm.nih.gov/32692358/ DOI: 10.1093/jn/nxaa203
Complete structured claim and evidence

Where it participates (unsigned role)

Oat beta-glucan in doses at or above 3 grams per day reduced low-density lipoprotein and total cholesterol relative to control by 0.25 mmol/L with 95% CI 0.20 to 0.30 and 0.30 mmol/L with 95% CI 0.24 to 0.35 respectively, there was no significant effect on high-density lipoprotein cholesterol or triglycerides and no evidence that dose across a range of 3.0 to 12.4 grams per day or duration of treatment from 2 to 12 weeks influenced the results, and LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol.
Oat mixed-linkage beta-(1->3)/(1->4)-glucan → LDL cholesterol concentration source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/glucan-research/25411276.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "33075c61a20f22975ba8719b6ef8834ce254f1d4e3ede6ca5d89cd4d81a82b28", "start_char": 0, "end_char": 2072, "text_sha256": "33075c61a20f22975ba8719b6ef8834ce254f1d4e3ede6ca5d89cd4d81a82b28"}
experimental_model
Random-effects meta-analysis and meta-regression of 28 randomised controlled trials at or above 3 grams per day
exposure
Oat beta-glucan at 3.0 to 12.4 grams per day against an appropriate control for 2 to 12 weeks
limitations
A meta-analysis with some indication of heterogeneity. The diabetes subgroup rests on few studies, and in-house study reports from a commercial source were among those searched.
nutrient_topic
Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
organism
Human
plain_language
Three grams a day takes about a quarter of a millimole off the harmful cholesterol and leaves the other lipids alone.
primary_references
[bg-p25411276] Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. (2014). https://pubmed.ncbi.nlm.nih.gov/25411276/ DOI: 10.3945/ajcn.114.086108
tissue_or_cell_type
Serum lipids
Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 489–500
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Random-effects meta-analysis and meta-regression of 28 randomised controlled trials at or above 3 grams per day · source_derived_draft · unverified_draft
### bg-oat-glucan-lowers-ldl Oat beta-glucan in doses at or above 3 grams per day reduced low-density lipoprotein and total cholesterol relative to control by 0.25 mmol/L with 95% CI 0.20 to 0.30 and 0.30 mmol/L with 95% CI 0.24 to 0.35 respectively, there was no significant effect on high-density lipoprotein cholesterol or triglycerides and no evidence that dose across a range of 3.0 to 12.4 grams per day or duration of treatment from 2 to 12 weeks influenced the results, and LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: Three grams a day takes about a quarter of a millimole off the harmful cholesterol and leaves the other lipids alone. organism: Human tissue_or_cell_type: Serum lipids experimental_model: Random-effects meta-analysis and meta-regression of 28 randomised controlled trials at or above 3 grams per day limitations: A meta-analysis with some indication of heterogeneity. The diabetes subgroup rests on few studies, and in-house study reports from a commercial source were among those searched. exposure: Oat beta-glucan at 3.0 to 12.4 grams per day against an appropriate control for 2 to 12 weeks evidence_span: {"source_cache": "artifacts/glucan-research/25411276.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "33075c61a20f22975ba8719b6ef8834ce254f1d4e3ede6ca5d89cd4d81a82b28", "start_char": 0, "end_char": 2072, "text_sha256": "33075c61a20f22975ba8719b6ef8834ce254f1d4e3ede6ca5d89cd4d81a82b28"} [bg-p25411276] Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. (2014). https://pubmed.ncbi.nlm.nih.gov/25411276/ DOI: 10.3945/ajcn.114.086108
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Fasting triglyceride concentration